Neos Therapeutics (NASDAQ:NEOS) released its quarterly earnings results on Thursday. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.09, Bloomberg Earnings reports. The company had revenue of $15.64 million during the quarter, compared to the consensus estimate of $16.70 million.
Neos Therapeutics stock traded up $0.16 on Friday, hitting $1.82. 357,489 shares of the stock traded hands, compared to its average volume of 212,378. The company has a debt-to-equity ratio of 41.70, a quick ratio of 1.27 and a current ratio of 1.49. The stock has a market capitalization of $82.54 million, a price-to-earnings ratio of -1.14 and a beta of 1.19. The firm has a fifty day moving average of $1.36. Neos Therapeutics has a 1 year low of $1.13 and a 1 year high of $6.30.
NEOS has been the subject of several recent research reports. Cantor Fitzgerald lowered their price objective on Neos Therapeutics from $20.00 to $10.00 and set an “overweight” rating for the company in a research report on Wednesday, June 12th. ValuEngine raised Neos Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Finally, Zacks Investment Research lowered Neos Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Neos Therapeutics currently has a consensus rating of “Buy” and an average price target of $6.81.
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
See Also: Commodities
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.